Access to innovation through the national early access program and clinical trials for patients with malignant melanoma

Autor: Claire, Christen, Laetitia, Belgodère, Bernard, Guillot, Céline, Jumeau, Annie, Lorence, Ghania, Kerouani-Lafaye, Liora, Brunel, Florence, Turcry, Adrien, Monard, Francoise, Grudé, Gaëlle, Guyader, Lotfi, Boudali, Nicolas, Albin

Publikováno v: Cancer. 127(13)

The arrival of immunotherapies and targeted therapies challenged the authorities to make them available as soon as possible. France has effective tools, such as clinical trials (CTs) and a national early access program (temporary authorizations for u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::92e80cdab7e9bebf06ee70ee955cf8e3
https://pubmed.ncbi.nlm.nih.gov/33788953

European regulation on orphan medicinal products: 10 years of experience and future perspectives

Autor: Kerstin, Westermark, Birthe Byskov, Holm, Mirjam, Söderholm, Jordi, Llinares-Garcia, Frida, Rivière, Stiina, Aarum, Florence, Butlen-Ducuing, Stelios, Tsigkos, Agnieszka, Wilk-Kachlicka, Cinzia, N'Diamoi, János, Borvendég, David, Lyons, Bruno, Sepodes, Brigitte, Bloechl-Daum, André, Lhoir, Mariana, Todorova, Ioannis, Kkolos, Kateřina, Kubáčková, Heidrun, Bosch-Traberg, Vallo, Tillmann, Veijo, Saano, Emmanuel, Héron, Rembert, Elbers, Miranda, Siouti, Judit, Eggenhofer, Patrick, Salmon, Maurizio, Clementi, Dainis, Krieviņš, Aušra, Matulevičiene, Henri, Metz, Albert Cilia, Vincenti, Albertha, Voordouw, Bożenna, Dembowska-Bagińska, Ana Corrêa, Nunes, Flavia Mirela, Saleh, Tatiana, Foltánová, Martin, Možina, Josep, Torrent i Farnell, Björn, Beerman, Segundo, Mariz, Marie Pauline, Evers, Lesley, Greene, Sigurdur, Thorsteinsson, Lars, Gramstad, Maria, Mavris, Fabrizia, Bignami, Annie, Lorence, Chantal, Belorgey

Publikováno v: Nature reviews. Drug discovery. 10(5)

In 2000, regulation on orphan medicinal products was adopted in the European Union with the aim of benefiting patients who suffer from serious, rare conditions for which there is currently no satisfactory treatment. Since then, more than 850 orphan d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::89d8998cffc4d17daac011c4aa2f5623
https://pubmed.ncbi.nlm.nih.gov/21532564

Judicialización de medicamentos huérfanos en Brasil: la justiciabilidad de un objeto políticamente "no palatable"Judicialization of orphan drugs in Brazil: the justiciability of a politically unpalatable issue.

Autor: Cardoso, João Vitor

Publikováno v: International Journal of Constitutional Law; Oct2021, Vol. 19 Issue 4, p1322-1350, 29p

European regulation on orphan medicinal products: 10 years of experience and future perspectives.

Autor: Committee for Orphan Medicinal Products and the European Medicines (CORPORATE AUTHOR), Westermark, Kerstin (AUTHOR), Holm, Birthe Byskov (AUTHOR), Söderholm, Mirjam (AUTHOR), Llinares-Garcia, Jordi (AUTHOR), Rivière, Frida (AUTHOR), Aarum, Stiina (AUTHOR), Butlen-Ducuing, Florence (AUTHOR), Tsigkos, Stelios (AUTHOR), Wilk-Kachlicka, Agnieszka (AUTHOR), N'Diamoi, Cinzia (AUTHOR), Borvendég, János (AUTHOR), Lyons, David (AUTHOR), Sepodes, Bruno (AUTHOR), Bloechl-Daum, Brigitte (AUTHOR), Lhoir, André (AUTHOR), Todorova, Mariana (AUTHOR), Kkolos, Ioannis (AUTHOR), Kubáčková, Kateřina (AUTHOR), Bosch-Traberg, Heidrun (AUTHOR)

Publikováno v: Nature Reviews Drug Discovery. May2011, Vol. 10 Issue 5, p341-349. 9p. 2 Charts, 1 Graph.

Table ronde 2. (French)

Publikováno v: Médecine Sciences; Apr2014 Supplement 1, Vol. 30, p14-20, 7p